.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Chinese Patent Office
Accenture
Deloitte
Dow
Moodys
Johnson and Johnson
US Army
McKesson
Mallinckrodt

Generated: November 19, 2017

DrugPatentWatch Database Preview

Taro Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for TARO PHARM, and what generic alternatives to TARO PHARM drugs are available?

TARO PHARM has thirty-eight approved drugs.

There are three US patents protecting TARO PHARM drugs. There are two tentative approvals on TARO PHARM drugs.

There are twenty-five patent family members on TARO PHARM drugs in thirteen countries and twenty-two supplementary protection certificates in nine countries.

Summary for Taro Pharm

International Patents:25
US Patents:3
Tradenames:34
Ingredients:32
NDAs:38
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro Pharm Inds
CICLOPIROX
ciclopirox
SOLUTION;TOPICAL078144-001Sep 18, 2007ATRXNoNo► Subscribe► Subscribe► Subscribe
Taro Pharm
NORTRIPTYLINE HYDROCHLORIDE
nortriptyline hydrochloride
CAPSULE;ORAL075520-003May 8, 2000ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro Pharms
PLIAGLIS
lidocaine; tetracaine
CREAM;TOPICAL021717-001Jun 29, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Taro Pharm Inds
FLUTICASONE PROPIONATE
fluticasone propionate
OINTMENT;TOPICAL077145-001Jun 14, 2005DISCNNoNo► Subscribe► Subscribe► Subscribe
Taro Pharm
CIPROFLOXACIN HYDROCHLORIDE
ciprofloxacin hydrochloride
TABLET;ORAL076912-001Feb 18, 2005ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro Pharm
WARFARIN SODIUM
warfarin sodium
TABLET;ORAL040301-005Jul 15, 1999ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro Pharm
FELBAMATE
felbamate
TABLET;ORAL207093-001Apr 20, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro Pharm
FELBAMATE
felbamate
TABLET;ORAL207093-002Apr 20, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro Pharm
NYSTATIN
nystatin
SUSPENSION;ORAL062876-001Feb 29, 1988AARXNoNo► Subscribe► Subscribe► Subscribe
Taro Pharm
FELBAMATE
felbamate
SUSPENSION;ORAL206314-001Jun 16, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Taro Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Taro Pharms
PLIAGLIS
lidocaine; tetracaine
CREAM;TOPICAL021717-001Jun 29, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for TARO PHARM drugs

Drugname Dosage Strength Tradename Submissiondate
malathion
Topical Lotion0.5%
OVIDE
3/16/2011

Non-Orange Book Patents for Taro Pharm

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,039,657Process for preparing malathion for pharmaceutical use► Subscribe
8,957,238Process for preparing malathion for pharmaceutical use► Subscribe
8,536,155Process for preparing malathion for pharmaceutical use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Taro Pharm Drugs

Country Document Number Estimated Expiration
Portugal1244401► Subscribe
China101219108► Subscribe
European Patent Office1702597► Subscribe
Austria345757► Subscribe
China101287374► Subscribe
Japan2007217431► Subscribe
Japan2009500422► Subscribe
Japan2003510259► Subscribe
European Patent Office1244401► Subscribe
Germany60032021► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Taro Pharm Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1304992/01Switzerland► SubscribePRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
01C/045Belgium► SubscribePRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
C0014France► SubscribePRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
00085Netherlands► SubscribePRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
C0012France► SubscribePRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
2013025,C1304992Lithuania► SubscribePRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
C0004France► SubscribePRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
C0038France► SubscribePRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
01C/013Belgium► SubscribePRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Julphar
McKesson
Fuji
Harvard Business School
Moodys
US Department of Justice
Queensland Health
Daiichi Sankyo
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot